Rybelsus vs Ozempic in Canada: Oral vs Injectable Semaglutide
If you have type 2 diabetes in Canada, you may have heard of both Rybelsus and Ozempic and wondered how they differ. The short answer: they are the same active drug, semaglutide, delivered two different ways. Rybelsus is a tablet you swallow once a day; Ozempic is an injection you give yourself once a week. In Canada both are approved to help control blood sugar in adults with type 2 diabetes, not for weight loss. This guide compares their approved uses, how you take them, effectiveness, safety and cost at a general level. It is educational only, not medical advice, and only a licensed prescriber can decide whether either is right for you.
Book Your Appointment Now
Rybelsus and Ozempic are both semaglutide, Health Canada–approved for type 2 diabetes in adults, not for weight loss. The key difference is delivery: Rybelsus is a daily oral tablet with a strict empty-stomach routine, Ozempic a weekly injection. A prescriber must assess suitability, a prescription is never guaranteed, and this is not medical advice.
- Both Rybelsus and Ozempic contain the same active ingredient, semaglutide, and are Health Canada–approved to improve blood-sugar control in adults with type 2 diabetes as an adjunct to diet and exercise (Rybelsus and Ozempic product monographs, Novo Nordisk Canada).
- In Canada, neither Ozempic nor Rybelsus is approved for weight loss. Wegovy is the semaglutide product Health Canada has authorized for chronic weight management, and it is dosed differently (Health Canada).
- Rybelsus is a once-daily oral tablet (3 mg, 7 mg, 14 mg) taken on an empty stomach with a small sip of plain water, followed by waiting at least 30 minutes before eating, drinking or taking other oral medicines (Rybelsus product monograph).
- Ozempic is a once-weekly subcutaneous injection, titrated by a prescriber (commonly starting at 0.25 mg and increasing toward 0.5, 1 or up to 2 mg weekly) (Ozempic product monograph).
- Health Canada's January 2026 advisory warned people not to buy or use fake or unauthorized GLP-1 products and advised buying prescription drugs only from licensed pharmacies (Health Canada recalls and safety alerts).
Clinical content is reviewed for accuracy and scope. TelePlus Care appointments go ahead only when a doctor agrees it is the right call, after a real assessment, and the doctor will explain the next step if virtual care is not the right fit.
Same molecule, two different delivery systems
Rybelsus and Ozempic are both brand names for semaglutide, made by Novo Nordisk. Semaglutide belongs to the GLP-1 receptor agonist class: it mimics an incretin hormone your gut releases after eating, which helps the pancreas release insulin when blood sugar is high, lowers glucagon, and slows how quickly the stomach empties. Diabetes Canada's clinical practice guidelines recognize GLP-1 receptor agonists as an option for adults with type 2 diabetes and inadequate glycemic control, and generally favour them for people with established cardiovascular disease, high cardiovascular risk, or chronic kidney disease. The core difference between these two products isn't the drug itself, it's the delivery. Rybelsus is a tablet swallowed once daily; Ozempic is an injection given once weekly. That single difference shapes dosing, absorption, daily routine and, for some people, the side-effect experience. Everything below is general education for people in Canada, not medical advice, and a licensed prescriber must decide whether either is appropriate for you.
- Same active ingredient: semaglutide, a GLP-1 receptor agonist
- Rybelsus = daily oral tablet; Ozempic = weekly injection
- A prescriber assesses suitability; this article is not a substitute for that
What each is approved for in Canada (and what it isn't)
Both products are Health Canada–approved to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise. Ozempic has been authorized in Canada since 2018; Rybelsus was approved as the first oral GLP-1 tablet. Both also carry indications related to cardiovascular risk reduction in appropriate adults with type 2 diabetes: Ozempic's is supported by the SUSTAIN-6 outcomes trial, and Rybelsus received a Health Canada indication in 2026 to reduce the risk of major adverse cardiovascular events in eligible patients. One point matters a great deal: neither Ozempic nor Rybelsus is approved in Canada for weight loss. The semaglutide product Health Canada authorized for chronic weight management is Wegovy, prescribed for adults with obesity, or overweight with a weight-related condition, and dosed differently. Prescribers sometimes use diabetes medicines off-label, but that is a case-by-case clinical decision, never a guarantee. Always confirm current indications in the product monograph.
- Rybelsus: type 2 diabetes glycemic control (plus a 2026 cardiovascular indication)
- Ozempic: type 2 diabetes glycemic control plus cardiovascular risk reduction
- Wegovy, not Ozempic or Rybelsus, is the semaglutide approved for weight management in Canada
Daily pill vs weekly injection: how you actually take them
The practical routines are quite different, and the details matter. Rybelsus comes in 3 mg, 7 mg and 14 mg tablets. Treatment usually starts at 3 mg daily for about 30 days to improve tolerability (this dose is for getting used to the drug, not primarily for glucose control), then steps up to 7 mg, and to 14 mg if more control is needed. The absorption rules are strict: take it after waking on an empty stomach with no more than roughly 120 mL (about 4 oz) of plain water, swallow it whole without splitting, crushing or chewing, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Food and extra liquid sharply reduce how much drug is absorbed. Ozempic is a once-weekly subcutaneous injection from a prefilled pen, into the abdomen, thigh or upper arm, on the same day each week, at any time, with or without food.
- Rybelsus: once daily, empty stomach, small sip of plain water, wait 30+ minutes
- Ozempic: once weekly injection, same day each week, with or without food
- Both are titrated slowly by a prescriber; starter doses are for tolerability, not final therapy
How well do they work, and what the evidence shows
Both forms of semaglutide can meaningfully lower A1C (average blood sugar) in adults with type 2 diabetes, and many people also see modest weight reduction as a secondary effect, though individual response varies. Comparing them head-to-head is not straightforward. Some evidence suggests the injectable can reach higher drug exposure at its top doses, but real-world results depend heavily on the dose used and on adherence, and Rybelsus's strict empty-stomach routine can affect how much is absorbed day to day. Diabetes Canada notes that GLP-1 receptor agonists can offer glycemic benefits together with cardiovascular and kidney benefits for appropriate patients. In practice, which option is 'better' depends on your overall health profile, other conditions and medications, whether you would rather inject weekly or follow a precise daily fasting routine, and cost or coverage. Your prescriber weighs all of this. Treat any efficacy figures you see online with caution and confirm details against the product monograph.
- Both can lower A1C; weight change is a secondary, variable effect
- Adherence and the fasting rule strongly influence Rybelsus's real-world effect
- 'Better' depends on your health profile and preferences, decided with a prescriber
Side effects, cautions and who should be careful
The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea or constipation. These are usually mild and tend to ease as the dose is slowly increased. The product monographs also flag more serious considerations. In animal studies, semaglutide caused thyroid C-cell tumours, so it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Caution applies with a history of pancreatitis or gallbladder disease, and diabetic retinopathy can worsen in some patients. The risk of low blood sugar (hypoglycemia) rises when semaglutide is combined with insulin or a sulfonylurea. It is not for type 1 diabetes or diabetic ketoacidosis, and use in pregnancy or breastfeeding is generally not recommended, discuss this with your prescriber. This list is not exhaustive; the product monograph and your pharmacist are the authoritative sources. Seek urgent care for severe abdominal pain or signs of a serious allergic reaction, these medicines are not for emergencies.
- Most common: nausea, vomiting, diarrhea, constipation, usually easing over time
- Contraindicated with personal or family history of medullary thyroid cancer or MEN 2
- Higher hypoglycemia risk with insulin or sulfonylureas; not for type 1 diabetes or DKA
- For severe symptoms call 911 or go to the emergency department
Cost, coverage, prescriptions and avoiding counterfeits
Both Rybelsus and Ozempic are prescription-only in Canada. A licensed prescriber, such as a physician or nurse practitioner, must assess whether either is suitable, and a prescription is never guaranteed. Out-of-pocket cost varies by product, dose, pharmacy, and whether you have public or private drug coverage; provincial formularies and private plans differ, and coverage often depends on a documented type 2 diabetes diagnosis. Ask your pharmacist for current pricing and check your specific plan rather than relying on figures you find online. Just as important is where you buy. Health Canada's January 2026 advisory urged people not to buy or use fake or unauthorized GLP-1 products, warning they may contain too much active drug, too little, none at all, or contaminants, and advised purchasing prescription drugs only from licensed pharmacies. Avoid social media sellers, unauthorized websites and 'fauxzempic' offers. If you are unsure whether a pharmacy is legitimate, verify it with your provincial regulatory college.
- Prescription-only; a prescriber assesses suitability and approval is not guaranteed
- Cost and coverage vary by province, plan and diagnosis; confirm with your pharmacist
- Buy only from licensed pharmacies; Health Canada warns against counterfeit GLP-1 products
Rybelsus vs Ozempic in Canada — Fast, Convenient Virtual Care
Connect with a licensed healthcare provider from the comfort of your home. No referral needed — book your virtual appointment today.
Book Your Appointment NowExplore Our Canada Services
Teleplus care clinic is not an urgent care clinic. If you have an emergency please call911 or go to the nearest urgent care facility.
